Skip to Main Content

INFORMATION FOR

Nicholas Blondin, MD

Assistant Professor; Assistant Professor, Clinical Neurology

Contact Information

Nicholas Blondin, MD

Office Location

Mailing Address

  • Yale Cancer Center

    5520 Park Avenue

    Trumbull, CT 06611

    United States

Research Summary

Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center.

Extensive Research Description

Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center.

Coauthors

Research Interests

Neurology

Selected Publications

  • BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASISKumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Sharma A, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Matsutani M, Sales E, Sweed N, Dugan M, Kesari S. BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASIS Neuro-Oncology 2022, 24: vii4-vii5. DOI: 10.1093/neuonc/noac209.015.
  • NIMG-105. DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMASKim L, De Feyter H, de Graaf R, Fulbright R, Liu Y, Rothman D, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Corbin Z. NIMG-105. DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMAS Neuro-Oncology 2022, 24: vii189-vii189. PMCID: PMC9660955, DOI: 10.1093/neuonc/noac209.723.
  • TRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with HyperostosisJin L, Vetsa S, Vasandani S, Nadar A, Youngblood M, Gupte T, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Gorelick E, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, Marianayagam N, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. TRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with Hyperostosis Journal Of Neurological Surgery Part B Skull Base 2022, 83: s1-s270. DOI: 10.1055/s-0042-1743640.
  • INNV-09. SURGICAL STRATEGIES FOR OLDER PATIENTS WITH GLIOBLASTOMABarak T, Hwang L, Chen J, Jin L, Miyagishima D, Yalcin K, Ogilvie S, Antonios J, Theriault B, Huttner A, McGuone D, Lifton N, Blondin N, Corbin Z, Zhang Y, Gunel M, Erson-Omay Z, Fulbright R, Tabar T, Moliterno-Gunel J. INNV-09. SURGICAL STRATEGIES FOR OLDER PATIENTS WITH GLIOBLASTOMA Neuro-Oncology 2021, 23: vi107-vi107. PMCID: PMC8598632, DOI: 10.1093/neuonc/noab196.421.
  • NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMASJin L, Youngblood M, Gupte T, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS Neuro-Oncology 2021, 23: vi144-vi144. PMCID: PMC8598770, DOI: 10.1093/neuonc/noab196.562.
  • BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCERKumthekar P, Blouw B, Mayer J, Fisher D, Dugan M, Azadi A, Blondin N. BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER Neuro-Oncology 2021, 23: vi10-vi10. PMCID: PMC8598619, DOI: 10.1093/neuonc/noab196.036.
  • INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMABlondin N, Fulbright R, Huttner A, Moliterno-Gunel J. INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA Neuro-Oncology 2021, 23: vi106-vi106. DOI: 10.1093/neuonc/noab196.419.
  • INNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCERStuhlmiller T, Shapiro M, Wasserman A, Osking Z, Shrager J, Federowicz B, Warner M, Friedland J, Musella A, Blondin N, Fonkem E, Wong E, Kesari S. INNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCER Neuro-Oncology 2021, 23: vi113-vi113. DOI: 10.1093/neuonc/noab196.448.
  • QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTSBlondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.
  • ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Paul Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.
  • ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMABarkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.
  • INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS.Kumar Reddy N, Blondin N. INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS. Neuro-Oncology 2019, 21: vi135-vi135. PMCID: PMC6847258, DOI: 10.1093/neuonc/noz175.566.
  • Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastomaKelly J, Proescholdt C, Blondin N. Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastoma 2019, lb-163-lb-163. DOI: 10.1158/1538-7445.sabcs18-lb-163.
  • Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastomaKelly J, Proescholdt C, Blondin N. Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastoma Cancer Research 2019, 79: lb-163-lb-163. DOI: 10.1158/1538-7445.am2019-lb-163.
  • ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.
  • HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVALBlondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.
  • QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENTBlondin N. QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT Neuro-Oncology 2018, 20: vi214-vi215. PMCID: PMC6217477, DOI: 10.1093/neuonc/noy148.890.
  • Primary CNS LymphomaBlondin N, Baehring J, Hochberg F. Primary CNS Lymphoma 2014, 308-315. DOI: 10.1002/9781118589199.ch48.
  • Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (IN7-1.009)Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (IN7-1.009) Neurology 2012, 78: in7-1.009-in7-1.009. DOI: 10.1212/wnl.78.1_meetingabstracts.in7-1.009.
  • Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (P07.148)Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (P07.148) Neurology 2012, 78: p07.148-p07.148. DOI: 10.1212/wnl.78.1_meetingabstracts.p07.148.

Clinical Trials